Therapeutic Vaccines for Cancer: an Overview of Clinical Trials

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2014 Jul 9

PMID 25001465

Citations 361

Authors

Ignacio Melero

Gustav Gaudernack

Winald Gerritsen

Christoph Huber

Giorgio Parmiani

Suzy Scholl

Nicholas Thatcher

John Wagstaff

Christoph Zielinski

Ian Faulkner

Hakan Mellstedt

Affiliations

Soon will be listed here.

Abstract

The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.

Citing Articles

Advancement insights in cancer vaccines: mechanisms, types, and clinical applications.

Kamel G, Attia R, Al-Noman H, Salama L Mol Biol Rep. 2025; 52(1):290.

PMID: 40053260 DOI: 10.1007/s11033-025-10370-0.

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Respiratory delivered vaccines: Current status and perspectives in rational formulation design.

Wu L, Xu W, Jiang H, Yang M, Cun D Acta Pharm Sin B. 2025; 14(12):5132-5160.

PMID: 39807330 PMC: 11725141. DOI: 10.1016/j.apsb.2024.08.026.

Metformin-based nanomedicines for reprogramming tumor immune microenvironment.

Liu J, Li X, Li Y, Gong Q, Luo K Theranostics. 2025; 15(3):993-1016.

PMID: 39776799 PMC: 11700864. DOI: 10.7150/thno.104872.

Whole-Cell Vaccine Preparation Through Prussian Blue Nanoparticles-Elicited Immunogenic Cell Death and Loading in Gel Microneedles Patches.

Fu W, Li Q, Sheng J, Wu H, Ma M, Zhang Y Gels. 2024; 10(12).

PMID: 39727596 PMC: 11675167. DOI: 10.3390/gels10120838.

References

DeNardo D, Brennan D, Rexhepaj E, Ruffell B, Shiao S, Madden S . Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1(1):54-67. PMC: 3203524. DOI: 10.1158/2159-8274.CD-10-0028. View

Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T . FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007; 13(3):902-11. DOI: 10.1158/1078-0432.CCR-06-2363. View

Baron C, Raposo G, Scholl S, Bausinger H, Tenza D, Bohbot A . Modulation of MHC class II transport and lysosome distribution by macrophage-colony stimulating factor in human dendritic cells derived from monocytes. J Cell Sci. 2001; 114(Pt 5):999-1010. DOI: 10.1242/jcs.114.5.999. View

Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H . Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004; 101(38):13885-90. PMC: 518848. DOI: 10.1073/pnas.0405884101. View

Correale P, Rotundo M, Del Vecchio M, Remondo C, Migali C, Ginanneschi C . Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010; 33(4):435-41. PMC: 7322625. DOI: 10.1097/CJI.0b013e3181d32f01. View

Formenti S, Demaria S . Systemic effects of local radiotherapy. Lancet Oncol. 2009; 10(7):718-26. PMC: 2782943. DOI: 10.1016/S1470-2045(09)70082-8. View

Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A . Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012; 109(15):5797-802. PMC: 3326498. DOI: 10.1073/pnas.1117208109. View

Tel J, Anguille S, Waterborg C, Smits E, Figdor C, de Vries I . Tumoricidal activity of human dendritic cells. Trends Immunol. 2013; 35(1):38-46. PMC: 7106406. DOI: 10.1016/j.it.2013.10.007. View

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

10.

Dillman R, Cornforth A, Depriest C, McClay E, Amatruda T, De Leon C . Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012; 35(8):641-9. DOI: 10.1097/CJI.0b013e31826f79c8. View

11.

Miles D, Roche H, Martin M, Perren T, Cameron D, Glaspy J . Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMC: 3228158. DOI: 10.1634/theoncologist.2010-0307. View

12.

Schuster S, Neelapu S, Gause B, Janik J, Muggia F, Gockerman J . Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011; 29(20):2787-94. PMC: 3139394. DOI: 10.1200/JCO.2010.33.3005. View

13.

Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V . Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med. 2009; 14(12):2748-59. PMC: 3822725. DOI: 10.1111/j.1582-4934.2009.00911.x. View

14.

Weden S, Klemp M, Gladhaug I, Moller M, Eriksen J, Gaudernack G . Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2010; 128(5):1120-8. DOI: 10.1002/ijc.25449. View

15.

Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-24. DOI: 10.1093/intimm/dxm057. View

16.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C . Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18(8):1254-61. DOI: 10.1038/nm.2883. View

17.

Keilholz U, Letsch A, Busse A, Asemissen A, Bauer S, Blau I . A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009; 113(26):6541-8. DOI: 10.1182/blood-2009-02-202598. View

18.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

19.

Burch P, Breen J, Buckner J, Gastineau D, Kaur J, Laus R . Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000; 6(6):2175-82. View

20.

Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J . Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate. 2009; 69(9):917-27. DOI: 10.1002/pros.20941. View